相关实验视频
Updated: Jul 24, 2025

09:58
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
3.5K
对欧米茄-3摄入量和神经保护性认知结果的系统审查
Ayesha Z Sherzai1, Alexander N Sherzai1, Dean Sherzai1
1Department of Neurology, Loma Linda University Health, Loma Linda, CA, USA (DS, AZS); and California State University, Los Angeles, CA, USA (ANS).
American journal of lifestyle medicine
|July 10, 2023
概括
n-3长链多不和脂肪酸 (LC PUFA) 显示出不一致的认知益处. 补充剂可能会为改善认知提供趋势,特别是在早期认知衰退的个体中,但效果并不确定.
科学领域:
- 神经科学是一个神经科学.
- 营养科学 营养科学
- 公共卫生 公共卫生
背景情况:
- 越来越多的人对n-3长链多不和脂肪酸 (LC PUFA) 的认知影响越来越感兴趣.
- 需要对LC PUFA认知影响的全面寿命数据,考虑到人口变化和研究局限性.
研究的目的:
- 系统地审查n-3s对人类认知的影响.
- 提供当前研究的概述,并建议未来的方向.
主要方法:
- 对PubMed,Web of Science和ProQuest Central (2000-2020年) 的高功率文章进行系统审查.
- 专注于评估LC PUFA认知状态作为主要结果的研究.
- 遵守PRISMA指南,以获得全面的概述.
主要成果:
- 观察到不一致的干预效应,并指出对特定群体和结果的好处.
- 有证据表明,如果需求已经满足,补充剂不会提供额外的好处,这可能会产生值效应.
- 在经历早期认知衰退的个体中观察到对认知功能改善的趋势.
结论:
- n-3 LC PUFA 对认知的影响是复杂的,并不是普遍确定的.
- 需要进一步的研究来澄清具体的益处,最佳剂量和目标人群.
- 对于特定的认知领域可能存在潜在的益处,特别是在现有认知衰退的人群中.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
159
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
159
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525

